/Amazon%20-%20Image%20by%20bluestork%20via%20Shutterstock.jpg)
Amazon.com (AMZN) is sharpening its healthcare ambitions with a calculated push, introducing a program that streamlines access to weight-loss treatments while fundamentally reengineering how GLP-1 therapies reach patients.
The move places the company in direct competition with entrenched leaders like Eli Lilly and Company (LLY) and Novo Nordisk A/S (NVO), but with a fundamentally different playbook built on integration and scale.